Short Communication - Journal of Aging and Geriatric Psychiatry (2024) Volume 8, Issue 2

Geriatric psychopharmacology: Optimizing mental health treatment in older adults.

Diane Gooding^*

Department of Public Health, University of Michigan, United States.

*Corresponding Author:

Gilda Ennis
Department of Public Health
University of Michigan.
E-mail: dgoding@wisc.edu

Received : 25-Jan-2024, Manuscript No. AAAGP-24-171831; Editor assigned : 28-Jan-2024, PreQC No. AAAGP-24-171831(PQ); Reviewed : 11-Jan-2024, QC No AAAGP-24-171831; Revised : 16-Jan-2024, Manuscript No. AAAGP-24-171831(R); Published : 22-Jan-2024 , DOI : 10.35841/aaagp-8.1.171

Citation:  Gooding D. Geriatric psychopharmacology: Optimizing mental health treatment in older adults. 2024;8(2):177.

Introduction

The aging population is rapidly increasing worldwide, leading to a higher prevalence of psychiatric disorders among older adults. Geriatric psychopharmacology focuses on the safe and effective use of medications to manage mental health conditions in this demographic. Older adults often present with complex clinical profiles, including comorbid medical conditions, polypharmacy, and altered pharmacokinetics, all of which require careful consideration when prescribing psychotropic medications. Understanding these unique factors is essential for improving mental health outcomes and quality of life in elderly patients.[1].

Depression and anxiety are among the most common psychiatric conditions in older adults, often coexisting with chronic illnesses such as cardiovascular disease, diabetes, or neurodegenerative disorders. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are frequently prescribed. However, clinicians must monitor for potential side effects, including hyponatremia, gastrointestinal disturbances, and increased risk of falls. Dose adjustments and gradual titration are key strategies to minimize adverse effects.[2].

Cognitive disorders, including Alzheimer’s disease and other dementias, present another major area of concern in geriatric psychiatry. Cholinesterase inhibitors and NMDA receptor antagonists are commonly used to slow cognitive decline and manage behavioral symptoms. Psychotropic medications such as antipsychotics may also be considered for severe agitation or psychosis, but their use must be limited due to increased risks of cardiovascular events, stroke, and mortality in older patients. Non-pharmacological interventions should always be prioritized when possible. [3].

Polypharmacy is a significant challenge in geriatric psychopharmacology. Older adults often take multiple medications for chronic physical illnesses, increasing the risk of drug-drug interactions. Prescribers must carefully review the patient’s medication list, consider potential interactions, and employ deprescribing strategies when appropriate. Regular medication reviews can reduce the likelihood of adverse effects and improve adherence, ensuring that mental health treatments are both safe and effective.[4].

Pharmacokinetics and pharmacodynamics undergo significant changes with aging. Reduced renal and hepatic function, altered body composition, and increased sensitivity to medications affect drug absorption, distribution, metabolism, and excretion. These changes necessitate starting doses lower than those typically used in younger adults, slow titration, and frequent monitoring of therapeutic response and adverse events. Personalized pharmacotherapy is critical for optimizing outcomes in older adults. [5].

Conclusion

Geriatric psychopharmacology plays a crucial role in managing psychiatric disorders in older adults, requiring careful consideration of comorbidities, polypharmacy, and age-related pharmacological changes. Personalized treatment, regular monitoring, patient and caregiver education, and integration of non-pharmacological interventions are essential strategies for optimizing mental health outcomes. As research advances, the future of geriatric psychopharmacology promises safer, more effective, and individualized approaches to improving the quality of life for the aging population.

References

1. Lewis UJ, Singh RN, Tutwiler GF, et al.Human growth hormone: a complex of proteins. InProceedings of the 1979 Laurentian Hormone Conference 1980. Academic press. 1980;477-08.

Indexed at, Google Scholar, Cross Ref

2. Chen EY, Liao YC, Smith DH, et al. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics. 1989;1;4(4):479-97.

Indexed at, Google Scholar, Cross Ref

3. Osman R, Mezei M, Engel S. The role of protein Stability patches in molecular recognition: A case study of the human growth hormone?receptor complex.J Comput Chem. 2016;15;37(10):913-9.

Indexed at, Google Scholar, Cross Ref

4. Hammer RE, Brinster RL, Rosenfeld MG. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature. 1985;315(6018):413-6.

Indexed at, Google Scholar, Cross Ref

5. Pearlman R, Bewley TA. Stability and characterization of human growth hormone. Stability and characterization of protein and peptide drugs. 1993;1-58.

Indexed at, Google Scholar, Cross Ref